We often underestimate how fundamentally different pivotal radiopharmaceutical trial development is from early-phase development. This session will explore the operational inflection points that determine whether phase I/II momentum translates into successful phase III delivery, including:

• Building scalable site, patient, vendor, and supply-chain strategies before phase III
• Regulatory, endpoint, and global operational challenges
• What successful programs do differently